Key facts
- It has raised $213.1M; the latest was Later Stage VC ($131.0M) in Aug 2025.
- Notable investors include Qiming Venture Partners, OrbiMed, BioTrack Capital, Boyuan Capital, TF Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Minghui Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Minghui Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Minghui Pharmaceutical
Operator of a biopharmaceutical firm intended to develop transformative medicines for patients with oncology and autoimmune conditions. The company offers proprietary antibody technologies, bispecific constructs and topical therapeutics, enabling healthcare providers treating complex diseases to access novel therapies with high clinical relevance.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Website
- minghuipharma.com/
- Ownership
- Privately Held (backing)
Minghui Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Minghui Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Minghui Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.